Trending Now
Why it may be Time to Buy the Dip in Sustainability...
The sustainability movement is likely to be the most important investment theme over the next ten years.
The transition...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
The Launch of AditxtScore™ for COVID-19 by Aditxt, Inc. (NASDAQ: ADTX)...
Several states, including Kentucky, are still experiencing a dramatic surge in COVID-19 cases. In addition, hospitals and caregivers are feeling the heat due to...
MAKE IT MODERN
LATEST REVIEWS
Neurocrine Biosciences Inc. (NASDAQ: NBIX) Reports INGREZZA net sales of $287...
Neurocrine Biosciences Inc. (NASDAQ: NBIX) has released its Q3 2021 financial results in which INGREZZA (valbenazine) net product sales were $287 million with over...
MAKE IT MODERN
PERFORMANCE TRAINING
Moderna Inc.’s (NASDAQ: MRNA) and Sinopharm Group Co Vaccines Receive Emergency Use Authorization in...
Kenya has given Sinopharm Group Co and Moderna Inc.’s (NASDAQ: MRNA) COVID-19 vaccines emergency use authorization, according to the Pharmacy and Poisons Board CEO...
The Case for Revisiting the CBD Space (RLBD, YCBD, TPB, MJNA, CWBHF)
The CBD market was the hottest growth idea in the financial world several years ago. That strength was driven by a simple...
Pardes Bioscience Inc. (NASDAQ: PRDS) Presents Late-Breaker Poster on PBI-451 Phase 1 Study Results
Pardes Bioscience Inc. (NASDAQ: PRDS) has announced a late-breaker poster presentation sharing clinical findings from the current PBI-0451 Phase 1 study to be presented...
Ovid Therapeutics Inc (NASDAQ:OVID) Awarded Rare Pediatric Disease Designation For OV101 By The FDA
Ovid Therapeutics Inc (NASDAQ:OVID) announced on June 19 that its OV101 Angelman syndrome treatment received rare pediatric disease designation from the Food and Drug...
AIM ImmunoTech (NYSEAMERICAN:AIM) Offers An Update On Commercial Launch Of Ampligen In Argentina
AIM ImmunoTech (NYSEAMERICAN:AIM) has given an update regarding Ampligen’s commercial launch in Argentina for severe Chronic Fatigue syndrome treatment.
Ampligen approved for severe CFS/ME in...
MAKE IT MODERN
